"cancer cells signaling pathway novel ligand design and synthesis interference with communication combined therapy"@en . "2014-12-31+01:00"^^ . "1"^^ . "Nov\u00E9 typy ligand\u016F pro interferenci komunikace rakovinov\u00FDch bun\u011Bk jako nov\u00E1 terapeutick\u00E1 strategie" . "2"^^ . . . . . . . "21"^^ . "0"^^ . "New types of ligands interfering with cancer cell communication as a new therapeutic strategy"@en . "21"^^ . "Cell communication is one of the most important processes in the multicellular organism and its disturbances can initiate cell transformations leading to tumor development. Corrections of these aberrations should have a high therapeutic effect.\u00A0 The presented proposal deals with the design, preparation, and optimization of new types of ligands for the interference with cancer signalling pathways assayed both in vitro and in vivo. We intend to focus mainly on the inhibition of vascular endothelial growth factor (VEGF) cancer signalling pathway, stimulation of cancer immune suppression and restoration of gap junction intercellular communication (GJIC). During the project we plan to develop therapeutically effective ligands for targeting various parts of these signalling pathways. Ligands with selectivity for various parts of the pathways, e.g. porphyrins, polymethinium salts, polysaccharides, immunoglobulins, lectins, and lanthanide complexes, will be used for verification of the proposed concept.\u00A0 We plan also to use these ligands as key parts of novel targeted combined anticancer therapy."@en . "2011-01-01+01:00"^^ . . "2014-04-18+02:00"^^ . . . "http://www.isvav.cz/projectDetail.do?rowId=GAP303/11/1291"^^ . . "Bun\u011B\u010Dn\u00E1 komunikace je jeden nejd\u016Fle\u017Eit\u011Bj\u0161\u00EDch proces\u016F v mnohobun\u011B\u010Dn\u00E9m organismu a jej\u00ED naru\u0161en\u00ED m\u016F\u017Ee iniciovat bun\u011B\u010Dnou p\u0159em\u011Bnu a podpo\u0159it vznik a rozvoj n\u00E1dor\u016F. Oprava t\u011Bchto chyb m\u016F\u017Ee m\u00EDt vysok\u00FD terapeutick\u00FD efekt. Prezentovan\u00FD projekt se zab\u00FDv\u00E1\u00A0 n\u00E1vrhem, p\u0159\u00EDpravou a optimalizaci nov\u00FDch typ\u016F ligand\u016F zasahuj\u00EDc\u00EDch do sign\u00E1ln\u00EDch drah rakovinov\u00FDch bun\u011Bk a testovan\u00FDch jak v in vitro tak in vivo syst\u00E9mu. Soust\u0159ed\u00EDme se hlavn\u011B na inhibici VEGF (vaskul\u00E1rn\u00ED endotheli\u00E1ln\u00ED r\u016Fstov\u00FD faktor) n\u00E1dorov\u00E9 sign\u00E1ln\u00ED dr\u00E1hy, stimulaci n\u00E1dorov\u00E9 imunitn\u00ED suprese a obnovu mezibun\u011B\u010Dn\u00E9 komunikace (gap junction intercellular communication -GJIC). V tomto projektu chceme vyvinout terapeuticky \u00FA\u010Dinn\u00E9 ligandy pro r\u016Fzn\u00E9 \u010D\u00E1sti t\u011Bchto sign\u00E1ln\u00EDch drah. Pro napln\u011Bn\u00ED tohoto konceptu budou pou\u017Eity ligandy se selektivitou pro danou \u010D\u00E1st (porfyriny, polymethinov\u00E9 sole, polysacharidy, imunoglobuliny, lektiny a lanthanoidov\u00E9 komplexy). Pl\u00E1nujeme tak\u00E9 pou\u017Eit tyto ligandy jako kl\u00ED\u010Dov\u00E9 \u010D\u00E1sti pro novou c\u00EDlenou kombinovanou protin\u00E1dorovou terapii." . . . "2015-05-22+02:00"^^ . "GAP303/11/1291" . . . . "Projekt v pr\u016Fb\u011Bhu 4 let splnil v\u0161echny stanoven\u00E9 c\u00EDle. Z\u00EDskan\u00E9 v\u00FDsledky jsou d\u016Fle\u017Eit\u00E9 z hlediska bun\u011B\u010Dn\u00E9 signalizace, rozpozn\u00E1v\u00E1n\u00ED nov\u00FDch sign\u00E1ln\u00EDch molekul a v nalezen\u00ED mo\u017Enosti interference s bun\u011B\u010Dnou komunikac\u00ED. V\u00FDstupem projektu je 13 kvalitn\u00EDch publikac\u00ED s IF, 3 kapitoly v knize a 4 patenty. \u010Cerp\u00E1n\u00ED finan\u010Dn\u00EDch prost\u0159edk\u016F bylo v souladu s pravidly GA\u010CR."@cs . . . "Project over 4 years has met all targets. The results are important for cell signaling, detection of new signaling molecules and for finding possibilities of interference with cellular communications. The output of the project is 13 high-quality publications with impact factors, 3 book chapters and 4 patents. Use of funds was in accordance with rules of GACR."@en . .